@misc{indiciaec03dfc43f6db,
  title = {Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells: Nafamostat is the most potent antiviral drug candidate},
  author = {Ko, M. and Jeon, S. and Ryu, W.-S. and Kim, S.},
  year = {2020},
  doi = {10.1101/2020.05.12.090035},
  url = {https://www.biorxiv.org/content/10.1101/2020.05.12.090035v1},
  note = {Source identifier: 10.1101/2020.05.12.090035}
}